ANDA 206846, held by Accord Hlthcare. Ondansetron Hydrochloride.
As of Nov 16, 2026, ANDA 206846 (Ondansetron Hydrochloride), held by Accord Hlthcare, was first approved by FDA on Jul 13, 2015, with 5 approved supplements and 0 published complete response letters.
Ondansetron Injection is a 5-HT 3 receptor antagonist indicated for the prevention of: nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. postoperative nausea and/or vomiting. 1.1 Prevention of Nausea and Vomiting Associated With Initial and Repeat Courses of Emetogenic Cancer Chemotherapy Ondansetron Injection is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin. Ondansetron Injection is approved for patients aged 6 months and older. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 13, 2015 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ondansetron HydrochlorideEQ 2MG BASE/ML · injectable;injection | Ondansetron Hydrochloride | Rx |
| Oct 13, 2026 | Supplement 10Labeling · Standard review | Approved | None posted |
| Oct 13, 2026 | Supplement 12Labeling · Standard review | Approved | None posted |
| May 24, 2023 | Supplement 8Labeling · Standard review | Approved | None posted |
| Oct 1, 2021 | Supplement 2Labeling · Standard review | Approved | None posted |
| Oct 1, 2021 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jul 13, 2015 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters